Redwood Bioscience, Inc.

Immunex Corporation

Polytherics Limited

Antitope Limited

The Brigham and Women's Hospital, Inc.

Celldex Therapeutics Limited

Proclara Biosciences, Inc.

C2n Diagnostics LLC

Syntimmune, Inc.

Abzena (uk) Limited

Robert George Edward Holgate

Francis Joseph Carr

Arron Hearn

Timothy Gareth Jones

David Rabuka

Timothy David Jones

Richard S Blumberg

Jay Rothstein

Susan Dana Jones

Francis J Carr

Yaron R Hadari

Diljeet Singh Athwal

Richard Fisher

Tim West

Monica Bertagnolli

Yu-Hwa Huang

Yan Yang

Derry Roopenian

Laurence J Blumberg

Amit Gandhi

Charles Yoon

Richard Weldon

Lida Kimmel

Brett Robinson

Sreekala Mandiyan

Richard A Fisher

Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer.

Humanized and affinity-matured anti-CEACAM1 antibodies

The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.

Antibody specific for CD22 and methods of use thereof

Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.

Anti-MET antibodies and methods of use thereof

Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.

Methods of immunosuppression comprising administering an anti-CD154 antibody

An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequence given in SEQ ID NO:33, wherein SEQ ID NO:33 is: EVQLVQSGXE XKKPGASVKV SCKXSGYTFT EYTIHWVXQA XGKGLEWIGN INPNXGGTTY NOKFEDRXTXTVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGOGTT VTVSS wherein: Xis A or P Xis V or L Xis A or T Xis R or K Xis P or H Xis N or Q Xis V or A; and Xis I or L whereby the heavy chain variable domain comprises up to 3 amino acid sequence modification(s) between positions 1-30, 36-49, 67-98 and 105-115 of SEQ ID NO: 33. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer.

Antibodies, uses thereof and conjugates thereof

An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: CDR1: EYTIH (SEQ ID NO: 33) CDR2: NINPNXGGTTYNQKFED (SEQ ID NO: 34) CDR3: XDY (SEQ ID NO: 35) wherein Xis N or Q, and Xis YWLF (SEQ ID NO: 39), GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), and wherein if Xis GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if Xis YWLF (SEQ ID NO: 39), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of disease, in particular cancers, particularly prostate cancer.

Anti-PSMA antibodies, uses thereof and conjugates thereof

Anti-CD154 antibody having improved binding, functional and safety characteristics

Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Humanized affinity matured anti-FcRn antibodies

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity

Provided herein is an isolated antibody or antigen-binding fragment that specifically binds tau, the antibody or fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region having amino acid sequences set forth herein. Also provided are methods of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more antibodies or fragments as described herein, wherein the antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy.

Humanized anti-tau antibodies

The invention provides an anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7, in particular, it inhibits binding of CTLA4 to human B7.1 and/or human B7.2. Specific antibodies are provided with specific variable region sequences as well as compositions comprising such antibodies for use in treating disease.

Humanised anti CTLA-4 antibodies

The present invention relates to novel humanised antibodies against human CD52 and their use in methods of treating or preventing human diseases.

Humanised anti-CD52 antibodies

Growing community of inventors

Royston, United Kingdom

Robert George Edward Holgate